drug
(glecaprevir + pibrentasvir)
Marketedupdated 5mo agoby $ABBV AbbVie Inc.
Approvedannual revenue · 2024–2024peak $1.4B
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying (glecaprevir + pibrentasvir)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 30, 2026
24 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (36)
- Dec 24, 2036patentUS 11246866*PED
- Jun 24, 2036formulationUS 11246866
- Dec 5, 2035patentUS 9321807*PED
- Dec 5, 2035patentUS 9321807*PED
- Nov 8, 2035patentUS RE48923*PED
- Nov 8, 2035patentUS RE48923*PED
- Jun 5, 2035compositionUS 9321807
- Jun 5, 2035compositionUS 9321807
- May 8, 2035compositionUS RE48923
- May 8, 2035compositionUS RE48923
- Sep 14, 2034patentUS 10286029*PED
- Sep 14, 2034patentUS 10286029*PED
- Sep 14, 2034patentUS 11484534*PED
- Mar 14, 2034method-of-use (U-3238)US 10286029
- Mar 14, 2034method-of-use (U-3237)US 10286029
- Mar 14, 2034method-of-use (U-3237)US 11484534
- Nov 18, 2032patentUS 8937150*PED
- Nov 18, 2032patentUS 8937150*PED
- Jul 19, 2032patentUS 8648037*PED
- Jul 19, 2032patentUS 8648037*PED
- May 18, 2032compositionUS 8937150
- May 18, 2032compositionUS 8937150
- Jan 19, 2032compositionUS 8648037
- Jan 19, 2032compositionUS 8648037
- May 6, 2031patentUS 9586978*PED4.6y
- May 6, 2031patentUS 9586978*PED4.6y
- Dec 10, 2030patentUS 10028937*PED4.2y
- Dec 10, 2030patentUS 10028937*PED4.2y
- Dec 10, 2030patentUS 10039754*PED4.2y
- Dec 10, 2030patentUS 10039754*PED4.2y
- Nov 6, 2030method-of-use (U-3238)US 95869784.1y
- Nov 6, 2030method-of-use (U-2141)US 95869784.1y
- Jun 10, 2030method-of-use (U-3237)US 100289373.7y
- Jun 10, 2030method-of-use (U-3238)US 100289373.7y
- Jun 10, 2030method-of-use (U-3238)US 100397543.7y
- Jun 10, 2030method-of-use (U-3237)US 100397543.7y
FDA exclusivities (9)
- Dec 10, 2028PEDPediatric (6mo bonus)2.2y
- Dec 10, 2028PEDPediatric (6mo bonus)2.2y
- Jun 10, 2028I-967Indication (3y)1.7y
- Jun 10, 2028ODE-372Orphan Drug (7y)1.7y
- Jun 10, 2028I-967Indication (3y)1.7y
- Jun 10, 2028ODE-372Orphan Drug (7y)1.7y
- Oct 30, 2026PEDPediatric (6mo bonus)24d
- Apr 30, 2026ODE-233Orphan Drug (7y)
- Apr 30, 2026ODE-232Orphan Drug (7y)
News(2)
- Enanta sheds staffers as key antiviral, immunology readouts loomAs antiviral specialist Enanta Pharmaceuticals endeavors to expand into immunology, the company has decided to lay off 37 employees, Fierce has learned.fiercebiotech · 5d ago
- Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialAtea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.fiercebiotech · 2mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that